<DOC>
	<DOC>NCT01891526</DOC>
	<brief_summary>To test whether patients with hepatic insufficiency can tolerate one oral dose of 9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered.</brief_summary>
	<brief_title>Single Dose of 9-cis-retinoic Acid in Hepatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>1. Have biopsy verified hepatic insufficiency 2. Medically stable. 3. Ultra sonic examination of lever within the past 3 months 4. No pregnancy documented in women. use of anticonception during study and 1 month after Exclusion criteria: 1. Odd blood counts and samples not related to hepatic disease 2. encephalopathy (&gt; grad II) 3. concomitant treatment with pharmaca that is metabolized by CYP3A4 in the liver. 4. Cardiac disease 5. Kidney disease 6. Epilepsia 7. Stroke 8. Esophagal bleeding 9. Severe ascites 10. HIVpositivity 11. Psychiatric disorder 12. Cancer 13. pregnancy or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Metabolisation of 9-cis-retinoic acid</keyword>
	<keyword>hepatic patients</keyword>
	<keyword>investigation of urine and blood samples</keyword>
</DOC>